Signal transduction in human cutaneous melanoma and target drugs

Current Cancer Drug Targets

Volumn 13, Issue 8, 2013, Pages 843-866

  Uzdensky, Anatoly B ^a,b   Demyanenko, Svetlana V ^a,b   Bibov, Mikhail Y ^a  

^a SOUTHERN FEDERAL UNIVERSITY   (Russian Federation)

^b ROSTOV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Drug; Melanoma; Metastasis; Signaling; Targeted therapy; Tumorigenesis

Indexed keywords

BETA CATENIN; BEVACIZUMAB; BORTEZOMIB; CELECOXIB; DASATINIB; EVEROLIMUS; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPILIMUMAB; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; N (6, 7 DIHYDRO 6 OXO 5H DIBENZ [B, D] AZEPIN 7 YL) 2, 2 DIMETHYL N' (2, 2, 3, 3, 3 PENTAFLUOROPROPYL) PROPANEDIAMIDE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C JUN; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SORAFENIB; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; TEMSIROLIMUS; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; WNT PROTEIN; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CUTANEOUS MELANOMA; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84888103141     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313080004     Document Type: Article

References (209)

1. Friedman, R. J.; Heilman, E. R. The pathology of malignant melanoma. Dermatol. Clin. 2002, 20, 659-676.
2. Lens, M. B.; Dawes, M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 2004, 150, 179-185.
3. Balch, C. M.; Gershenwald, J. E.; Soong, S. J.; Thompson, J. F.; Atkins, M. B.; Byrd, D. R.; Buzaid, A. C.; Cochran, A. J.; Coit, D. G.; Ding, S.; Eggermont, A. M.; Flaherty, K. T.; Gimotty, P. A.; Kirkwood, J. M.; McMasters, K. M.; Mihm, M. C., Jr.; Morton, D. L.; Ross, M. I.; Sober, A. J.; Sondak, V. K. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27, 6199-6206.
4. Coit, D. G.; Andtbacka, R.; Anker, C. J.; Bichakjian, C. K.; Carson, W. E., 3rd; Daud, A.; Dilawari, R. A.; Dimaio, D.; Guild, V.; Halpern, A. C.; Hodi, F. S., Jr.; Kelley, M. C.; Khushalani, N. I.; Kudchadkar, R. R.; Lange, J. R.; Lind, A.; Martini, M. C.; Olszanski, A. J.; Pruitt, S. K.; Ross, M. I.; Swetter, S. M.; Tanabe, K. K.; Thompson, J. A.; Trisal, V.; Urist, M. M. Melanoma. J. Natl. Comp. Canc. Netw. 2012, 10, 366-400.
5. Flaherty, K. T.; Yasothan, U.; Kirkpatrick, P. Vemurafenib. Nat. Rev. Drug Discov. 2011, 10, 811-812.
6. Sosman, J. A.; Kim, K. B.; Schuchter, L.; Gonzalez, R.; Pavlick, A. C.; Weber, J. S.; McArthur, G. A.; Hutson, T. E.; Moschos, S. J.; Flaherty, K. T.; Hersey, P.; Kefford, R.; Lawrence, D.; Puzanov, I.; Lewis, K. D.; Amaravadi, R. K.; Chmielowski, B.; Lawrence, H. J.; Shyr, Y.; Ye, F.; Li, J.; Nolop, K. B.; Lee, R. J.; Joe, A. K.; Ribas, A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366, 707-714.
7. Carnero, A. Targeting the cell cycle for cancer therapy. Br. J. Cancer. 2002, 87, 129-133.
8. Coqueret, O. Linking cyclins to transcriptional control. Gene. 2002, 299, 35-55.
9. Sulaimon, S. S.; Kitchell, B. E. The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J. Vet. Intern. Med. 2003, 17, 760-772.
10. Ibrahim, N.; Haluska, F. G. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu. Rev. Pathol. 2009, 4, 551-579.
11. Nelson, A. A.; Tsao, H. Melanoma and genetics. Clin. Dermatol. 2009, 27, 46-52.
12. Palmieri, G.; Capone, M.; Ascierto, M. L.; Gentilcore, G.; Stroncek, D. F.; Casula, M.; Sini, M. C.; Palla, M.; Mozzillo, N.; Ascierto, P. A. Main roads to melanoma. J. Transl. Med. 2009, 7, 86.
13. Giles, N.; Pavey, S.; Pinder, A.; Gabrielli, B. Multiple melanoma susceptibility factors function in an ultraviolet radiation response pathway in skin. Br. J. Dermatol. 2012, 166, 362-371.
14. Jenkins, N. C.; Liu, T.; Cassidy, P.; Leachman, S. A.; Boucher, K. M.; Goodson, A. G.; Samadashwily, G.; Grossman, D. The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene. 2011, 30, 265-274.
15. Bennett, D. C. How to make a melanoma: what do we know of the primary clonal events? Pigment. Cell. Melanoma Res. 2008, 21, 27-38.
16. Ohtani, N.; Yamakoshi, K.; Takahashi, A.; Hara, E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J. Med. Invest. 2004, 51, 146-153.
17. Sekulic, A.; Haluska, P., Jr.; Miller, A. J.; Genebriera De Lamo, J.; Ejadi, S.; Pulido, J. S.; Salomao, D. R.; Thorland, E. C.; Vile, R. G.; Swanson, D. L.; Pockaj, B. A.; Laman, S. D.; Pittelkow, M. R.; Markovic, S. N. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo. Clin. Proc. 2008, 83, 825-846.
18. Mihic, L. L.; Bulat, V.; Situm, M.; Krolo, I.; Seserko, A. The role of apoptosis in the pathogenesis of malignant melanoma. Coll. Antropol. 2010, 34 (Suppl 2), 303-306.
19. Bloethner, S.; Scherer, D.; Drechsel, M.; Hemminki, K.; Kumar, R. Malignant melanoma--a genetic overview. Actas Dermosifiliogr. 2009, 100 Suppl 1, 38-51.
20. Ha, L.; Ichikawa, T.; Anver, M.; Dickins, R.; Lowe, S.; Sharpless, N. E.; Krimpenfort, P.; Depinho, R. A.; Bennett, D. C.; Sviderskaya, E. V.; Merlino, G. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl. Acad. Sci. USA. 2007, 104, 10968-10973.
21. Dickson, M. A.; Schwartz, G. K. Development of cell-cycle inhibitors for cancer therapy. Curr. Oncol. 2009, 16, 36-43.
22. Zhang, X.; Chen, W.; Guillermo, R.; Chandrasekher, G.; Kaushik, R. S.; Young, A.; Fahmy, H.; Dwivedi, C. Alpha-santalol, a chemopreventive agent against skin cancer, causes G2/M cell cycle arrest in both p53-mutated human epidermoid carcinoma A431 cells and p53 wild-type human melanoma UACC-62 cells. BMC Res. Notes. 2010, 3, 220.
23. Aneja, R.; Asress, S.; Dhiman, N.; Awasthi, A.; Rida, P. C.; Arora, S. K.; Zhou, J.; Glass, J. D.; Joshi, H. C. Non-toxic melanoma therapy by a novel tubulin-binding agent. Int. J. Cancer. 2010, 126, 256-265.
24. Hamsa, T.; Kuttan, G. Ipobscurine, an indole alkaloid from Ipomoea obscura, inhibits tumor cell invasion and experimental metastasis by inducing apoptosis. J. Environ. Pathol. Toxicol. Oncol. 2011, 30, 163-178.
25. Smalley, K. S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol. 2010, 130, 28-37.
26. Platz, A.; Egyhazi, S.; Ringborg, U.; Hansson, J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol. Oncol. 2008, 1, 395-405.
27. Lefevre, G.; Calipel, A.; Mouriaux, F.; Hecquet, C.; Malecaze, F.; Mascarelli, F. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene. 2003, 22, 8813-8822.
28. Papp, T.; Pemsel, H.; Zimmermann, R.; Bastrop, R.; Weiss, D. G.; Schiffmann, D. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J. Med. Genet. 1999, 36, 610-614.
29. Demunter, A.; Stas, M.; Degreef, H.; De Wolf-Peeters, C.; van den Oord, J. J. Analysis of N-and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol. 2001, 117, 1483-1489.
30. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature. 2002, 417, 949-954.
31. Dong, J.; Phelps, R. G.; Qiao, R.; Yao, S.; Benard, O.; Ronai, Z.; Aaronson, S. A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003, 63, 3883-3885.
32. Kumar, R.; Angelini, S.; Czene, K.; Sauroja, I.; Hahka-Kemppinen, M.; Pyrhonen, S.; Hemminki, K. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 2003, 9, 3362-3368.
33. Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; O'Dwyer, P. J.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363, 809-819.
34. Woods, D.; Cherwinski, H.; Venetsanakos, E.; Bhat, A.; Gysin, S.; Humbert, M.; Bray, P. F.; Saylor, V. L.; McMahon, M. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol. Cell. Biol. 2001, 21, 3192-3205.
35. Sharma, A.; Trivedi, N. R.; Zimmerman, M. A.; Tuveson, D. A.; Smith, C. D.; Robertson, G. P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005, 65, 2412-2421.
36. Eisenmann, K. M.; VanBrocklin, M. W.; Staffend, N. A.; Kitchen, S. M.; Koo, H. M. Mitogen-activated protein kinase pathwaydependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res. 2003, 63, 8330-8337.
37. Cartlidge, R. A.; Thomas, G. R.; Cagnol, S.; Jong, K. A.; Molton, S. A.; Finch, A. J.; McMahon, M. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 2008, 21, 534-544.
38. Carbone, M.; Ferris, L. K.; Baumann, F.; Napolitano, A.; Lum, C. A.; Flores, E. G.; Gaudino, G.; Powers, A.; Bryant-Greenwood, P.; Krausz, T.; Hyjek, E.; Tate, R.; Friedberg, J.; Weigel, T.; Pass, H. I.; Yang, H. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med. 2012, 10, 179.
39. Tawbi, H.; Nimmagadda, N. Targeted therapy in melanoma. Biologics. 2009, 3, 475-484.
40. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S.; Fong, D.; Zhu, Y. L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S. H.; Schlessinger, J.; Zhang, K. Y.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA. 2008, 105, 3041-3046.
41. Puzanov, I.; Burnett, P.; Flaherty, K. T. Biological challenges of BRAF inhibitor therapy. Mol. Oncol. 2011, 5, 116-123.
42. Patel, S. P.; Kim, K. B. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert. Opin. Investig. Drugs. 2012, 21, 531-539.
43. Madhunapantula, S. V.; Robertson, G. P. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 2008, 68, 5-8.
44. Joseph, E. W.; Pratilas, C. A.; Poulikakos, P. I.; Tadi, M.; Wang, W.; Taylor, B. S.; Halilovic, E.; Persaud, Y.; Xing, F.; Viale, A.; Tsai, J.; Chapman, P. B.; Bollag, G.; Solit, D. B.; Rosen, N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA. 2010, 107, 14903-14908.
45. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507-16.
46. Falchook, G. S.; Lewis, K. D.; Infante, J. R.; Gordon, M. S.; Vogelzang, N. J.; Demarini, D. J.; Sun, P.; Moy, C.; Szabo, S. A.; Roadcap, L. T.; Peddareddigari, V. G.; Lebowitz, P. F.; Le, N. T.; Burris, H. A., 3rd; Messersmith, W. A.; O'Dwyer, P. J.; Kim, K. B.; Flaherty, K.; Bendell, J. C.; Gonzalez, R.; Kurzrock, R.; Fecher, L. A. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13, 782-789.
47. Halaban, R. Melanoma cell autonomous growth: the Rb/E2F pathway. Cancer Metastasis Rev. 1999, 18, 333-343.
48. Tsao, H.; Goel, V.; Wu, H.; Yang, G.; Haluska, F. G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 2004, 122, 337-341.
49. Lasithiotakis, K. G.; Sinnberg, T. W.; Schittek, B.; Flaherty, K. T.; Kulms, D.; Maczey, E.; Garbe, C.; Meier, F. E. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 2008, 128, 2013-2023.
50. Greger, J. G.; Eastman, S. D.; Zhang, V.; Bleam, M. R.; Hughes, A. M.; Smitheman, K. N.; Dickerson, S. H.; Laquerre, S. G.; Liu, L.; Gilmer, T. M. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 2012, 11, 909-920.
51. Shi, H.; Kong, X.; Ribas, A.; Lo, R. S. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011, 71, 5067-5074.
52. Karin, M.; Gallagher, E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life. 2005, 57, 283-295.
53. Lopez-Bergami, P.; Lau, E.; Ronai, Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat. Rev. Cancer. 2010, 10, 65-76.
54. Jorgensen, K.; Davidson, B.; Florenes, V. A. Activation of c-jun Nterminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma. Mod. Pathol. 2006, 19, 1446-1455.
55. Alexaki, V. I.; Javelaud, D.; Mauviel, A. JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res. 2008, 21, 429-438.
56. Lopez-Bergami, P. The role of mitogen-and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res. 2011, 24, 902-921.
57. Kennedy, N. J.; Davis, R. J. Role of JNK in tumor development. Cell Cycle. 2003, 2, 199-201.
58. Ivanov, V. N.; Kehrl, J. H.; Ronai, Z. Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis. Oncogene 2000, 19, 933-942.
59. Choi, B. Y.; Choi, H. S.; Ko, K.; Cho, Y. Y.; Zhu, F.; Kang, B. S.; Ermakova, S. P.; Ma, W. Y.; Bode, A. M.; Dong, Z. The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. Nat. Struct. Mol. Biol. 2005, 12, 699-707.
60. Rutberg, S. E.; Goldstein, I. M.; Yang, Y. M.; Stackpole, C. W.; Ronai, Z. Expression and transcriptional activity of AP-1, CRE, and URE binding proteins in B16 mouse melanoma subclones. Mol. Carcinog. 1994, 10, 82-87.
61. Lopez-Bergami, P.; Fitchman, B.; Ronai, Z. Understanding signaling cascades in melanoma. Photochem. Photobiol. 2008, 84, 289-306.
62. Berger, A. J.; Kluger, H. M.; Li, N.; Kielhorn, E.; Halaban, R.; Ronai, Z.; Rimm, D. L. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 2003, 63, 8103-8107.
63. Huangfu, W. C.; Qian, J.; Liu, C.; Liu, J.; Lokshin, A. E.; Baker, D. P.; Rui, H.; Fuchs, S. Y. Inflammatory signaling compromises cell responses to interferon alpha. Oncogene 2012, 31, 161-172.
64. Estrada, Y.; Dong, J.; Ossowski, L. Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res. 2009, 22, 66-76.
65. Bellacosa, A.; Kumar, C. C.; Di Cristofano, A.; Testa, J. R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 2005, 94, 29-86.
66. Madhunapantula, S. V.; Robertson, G. P. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2009, 22, 400-419.
67. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231-241.
68. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282, 1318-1321.
69. Stahl, J. M.; Sharma, A.; Cheung, M.; Zimmerman, M.; Cheng, J. Q.; Bosenberg, M. W.; Kester, M.; Sandirasegarane, L.; Robertson, G. P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004, 64, 7002-7010.
70. Dai, D. L.; Martinka, M.; Li, G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 2005, 23, 1473-1482.
71. Govindarajan, B.; Sligh, J. E.; Vincent, B. J.; Li, M.; Canter, J. A.; Nickoloff, B. J.; Rodenburg, R. J.; Smeitink, J. A.; Oberley, L.; Zhang, Y.; Slingerland, J.; Arnold, R. S.; Lambeth, J. D.; Cohen, C.; Hilenski, L.; Griendling, K.; Martinez-Diez, M.; Cuezva, J. M.; Arbiser, J. L. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Invest. 2007, 117, 719-729.
72. Chong, Z. Z.; Li, F.; Maiese, K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol. Histopathol. 2005, 20, 299-315.
73. Stahl, J. M.; Cheung, M.; Sharma, A.; Trivedi, N. R.; Shanmugam, S.; Robertson, G. P. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003, 63, 2881-2890.
74. Yin, Y.; Shen, W. H. PTEN: a new guardian of the genome. Oncogene 2008, 27, 5443-5453.
75. Ming, M.; He, Y. Y. PTEN: new insights into its regulation and function in skin cancer. J. Invest. Dermatol. 2009, 129, 2109-2112.
76. Sansal, I.; Sellers, W. R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004, 22, 2954-2963.
77. Tsao, H.; Niendorf, K. Genetic testing in hereditary melanoma. J. Am. Acad. Dermatol. 2004, 51, 803-808.
78. Saida, T. Recent advances in melanoma research. J. Dermatol. Sci. 2001, 26, 1-13.
79. Hocker, T.; Tsao, H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 2007, 28, 578-588.
80. Dankort, D.; Curley, D. P.; Cartlidge, R. A.; Nelson, B.; Karnezis, A. N.; Damsky, W. E., Jr.; You, M. J.; DePinho, R. A.; McMahon, M.; Bosenberg, M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 2009, 41, 544-552.
81. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell. 2007, 12, 9-22.
82. Populo, H.; Soares, P.; Lopes, J. M. Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert. Opin. Ther. Targets 2012, 16, 689-705.
83. Karbowniczek, M.; Spittle, C. S.; Morrison, T.; Wu, H.; Henske, E. P. mTOR is activated in the majority of malignant melanomas. J. Invest. Dermatol. 2008, 128, 980-987.
84. Populo, H.; Soares, P.; Faustino, A.; Rocha, A. S.; Silva, P.; Azevedo, F.; Lopes, J. M. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res. 2011, 24, 254-257.
85. Molhoek, K. R.; Brautigan, D. L.; Slingluff, C. L., Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J. Transl. Med. 2005, 3, 39.
86. Thallinger, C.; Werzowa, J.; Poeppl, W.; Kovar, F. M.; Pratscher, B.; Valent, P.; Quehenberger, P.; Joukhadar, C. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J. Invest. Dermatol. 2007, 127, 2411-2417.
87. Thallinger, C.; Poeppl, W.; Pratscher, B.; Mayerhofer, M.; Valent, P.; Tappeiner, G.; Joukhadar, C. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 2007, 79, 207-213.
88. Bundscherer, A.; Hafner, C.; Maisch, T.; Becker, B.; Landthaler, M.; Vogt, T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol. Rep. 2008, 19, 547-553.
89. Sinnberg, T.; Lasithiotakis, K.; Niessner, H.; Schittek, B.; Flaherty, K. T.; Kulms, D.; Maczey, E.; Campos, M.; Gogel, J.; Garbe, C.; Meier, F. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J. Invest. Dermatol. 2009, 129, 1500-1515.
90. Marone, R.; Erhart, D.; Mertz, A. C.; Bohnacker, T.; Schnell, C.; Cmiljanovic, V.; Stauffer, F.; Garcia-Echeverria, C.; Giese, B.; Maira, S. M.; Wymann, M. P. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol. Cancer Res. 2009, 7, 601-613.
91. Aziz, S. A.; Jilaveanu, L. B.; Zito, C.; Camp, R. L.; Rimm, D. L.; Conrad, P.; Kluger, H. M. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin. Cancer Res. 2010, 16, 6029-6039.
92. Hainsworth, J. D.; Infante, J. R.; Spigel, D. R.; Peyton, J. D.; Thompson, D. S.; Lane, C. M.; Clark, B. L.; Rubin, M. S.; Trent, D. F.; Burris, H. A., 3rd. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010, 116, 4122-4129.
93. Madonna, G.; Ullman, C. D.; Gentilcore, G.; Palmieri, G.; Ascierto, P. A. NF-kappaB as potential target in the treatment of melanoma. J. Transl. Med. 2012, 10, 53.
94. Ueda, Y.; Richmond, A. NF-kappaB activation in melanoma. Pigment Cell Res. 2006, 19, 112-124.
95. Yang, J.; Richmond, A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res. 2001, 61, 4901-4909.
96. Amiri, K. I.; Richmond, A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev. 2005, 24, 301-313.
97. Shishodia, S.; Aggarwal, B. B. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of antiapoptotic gene products, and enhances apoptosis. J. Biol. Chem. 2004, 279, 47148-47158.
98. Amiri, K. I.; Horton, L. W.; LaFleur, B. J.; Sosman, J. A.; Richmond, A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 2004, 64, 4912-4918.
99. Su, Y.; Amiri, K. I.; Horton, L. W.; Yu, Y.; Ayers, G. D.; Koehler, E.; Kelley, M. C.; Puzanov, I.; Richmond, A.; Sosman, J. A. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin. Cancer Res. 2010, 16, 348-357.
100. Yang, J.; Amiri, K. I.; Burke, J. R.; Schmid, J. A.; Richmond, A. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin. Cancer Res. 2006, 12, 950-960.
101. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127, 469-480.
102. Willert, K.; Jones, K. A. Wnt signaling: is the party in the nucleus? Genes Dev. 2006, 20, 1394-1404.
103. Sethi, J. K.; Vidal-Puig, A. Wnt signalling and the control of cellular metabolism. Biochem. J. 2010, 427, 1-17.
104. Larue, L.; Delmas, V. The WNT/Beta-catenin pathway in melanoma. Front. Biosci. 2006, 11, 733-742.
105. Bilic, J.; Huang, Y. L.; Davidson, G.; Zimmermann, T.; Cruciat, C. M.; Bienz, M.; Niehrs, C. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science. 2007, 316, 1619-1622.
106. Gao, C.; Chen, Y. G. Dishevelled: The hub of Wnt signaling. Cell Signal. 2010, 22, 717-727.
107. Worm, J.; Christensen, C.; Gronbaek, K.; Tulchinsky, E.; Guldberg, P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene. 2004, 23, 5215-5226.
108. Murakami, T.; Toda, S.; Fujimoto, M.; Ohtsuki, M.; Byers, H. R.; Etoh, T.; Nakagawa, H. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem. Biophys. Res. Commun. 2001, 288, 8-15.
109. Arozarena, I.; Bischof, H.; Gilby, D.; Belloni, B.; Dummer, R.; Wellbrock, C. In melanoma, beta-catenin is a suppressor of invasion. Oncogene. 2011, 30, 4531-4543.
110. Takahashi, Y.; Nishikawa, M.; Suehara, T.; Takiguchi, N.; Takakura, Y. Gene silencing of beta-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. Int. J. Cancer 2008, 123, 2315-2320.
111. Kielhorn, E.; Provost, E.; Olsen, D.; D'Aquila, T. G.; Smith, B. L.; Camp, R. L.; Rimm, D. L. Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int. J. Cancer 2003, 103, 652-656.
112. Sinnberg, T.; Menzel, M.; Ewerth, D.; Sauer, B.; Schwarz, M.; Schaller, M.; Garbe, C.; Schittek, B. beta-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One 2011, 6, e23429.
113. Sinnberg, T.; Menzel, M.; Kaesler, S.; Biedermann, T.; Sauer, B.; Nahnsen, S.; Schwarz, M.; Garbe, C.; Schittek, B. Suppression of casein kinase 1alpha in melanoma cells induces a switch in betacatenin signaling to promote metastasis. Cancer Res. 2010, 70, 6999-7009.
114. Delmas, V.; Beermann, F.; Martinozzi, S.; Carreira, S.; Ackermann, J.; Kumasaka, M.; Denat, L.; Goodall, J.; Luciani, F.; Viros, A.; Demirkan, N.; Bastian, B. C.; Goding, C. R.; Larue, L. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007, 21, 2923-2935.
115. Bellei, B.; Pitisci, A.; Catricala, C.; Larue, L.; Picardo, M. Wnt/beta-catenin signaling is stimulated by alpha-melanocytestimulating hormone in melanoma and melanocyte cells: implication in cell differentiation. Pigment Cell Melanoma Res. 2011, 24, 309-325.
116. Li, Y.; Bavarva, J. H.; Wang, Z.; Guo, J.; Qian, C.; Thibodeau, S. N.; Golemis, E. A.; Liu, W. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene 2011, 30, 2633-2643.
117. Reifenberger, J.; Knobbe, C. B.; Wolter, M.; Blaschke, B.; Schulte, K. W.; Pietsch, T.; Ruzicka, T.; Reifenberger, G. Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer. 2002, 100, 549-556.
118. You, L.; He, B.; Xu, Z.; Uematsu, K.; Mazieres, J.; Fujii, N.; Mikami, I.; Reguart, N.; McIntosh, J. K.; Kashani-Sabet, M.; McCormick, F.; Jablons, D. M. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 2004, 64, 5385-5389.
119. Shah, K. V.; Chien, A. J.; Yee, C.; Moon, R. T. CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J. Invest. Dermatol. 2008, 128, 2870-2879.
120. Lipson, E. J.; Drake, C. G. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 2011, 17, 6958-6962.
121. Mansh, M. Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J. Biol. Med. 2011, 84, 381-389.
122. Muller, C. S. Notch signaling and malignant melanoma. Adv. Exp. Med. Biol. 2012, 727, 258-264.
123. Hu, Y. Y.; Zheng, M. H.; Zhang, R.; Liang, Y. M.; Han, H. Notch signaling pathway and cancer metastasis. Adv. Exp. Med. Biol. 2012, 727, 186-198.
124. Balint, K.; Xiao, M.; Pinnix, C. C.; Soma, A.; Veres, I.; Juhasz, I.; Brown, E. J.; Capobianco, A. J.; Herlyn, M.; Liu, Z. J. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J. Clin. Invest. 2005, 115, 3166-3176.
125. Pinnix, C. C.; Lee, J. T.; Liu, Z. J.; McDaid, R.; Balint, K.; Beverly, L. J.; Brafford, P. A.; Xiao, M.; Himes, B.; Zabierowski, S. E.; Yashiro-Ohtani, Y.; Nathanson, K. L.; Bengston, A.; Pollock, P. M.; Weeraratna, A. T.; Nickoloff, B. J.; Pear, W. S.; Capobianco, A. J.; Herlyn, M. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009, 69, 5312-5320.
126. Hoek, K.; Rimm, D. L.; Williams, K. R.; Zhao, H.; Ariyan, S.; Lin, A.; Kluger, H. M.; Berger, A. J.; Cheng, E.; Trombetta, E. S.; Wu, T.; Niinobe, M.; Yoshikawa, K.; Hannigan, G. E.; Halaban, R. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 2004, 64, 5270-5282.
127. Liu, Z. J.; Xiao, M.; Balint, K.; Smalley, K. S.; Brafford, P.; Qiu, R.; Pinnix, C. C.; Li, X.; Herlyn, M. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and upregulating N-cadherin expression. Cancer Res. 2006, 66, 4182-4190.
128. Maier, M. M.; Gessler, M. Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. Biochem. Biophys. Res. Commun. 2000, 275, 652-660.
129. Topczewska, J. M.; Postovit, L. M.; Margaryan, N. V.; Sam, A.; Hess, A. R.; Wheaton, W. W.; Nickoloff, B. J.; Topczewski, J.; Hendrix, M. J. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med. 2006, 12, 925-932.
130. Strizzi, L.; Hardy, K. M.; Kirsammer, G. T.; Gerami, P.; Hendrix, M. J. Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab. Invest. 2011, 91, 819-824.
131. Hardy, K. M.; Kirschmann, D. A.; Seftor, E. A.; Margaryan, N. V.; Postovit, L. M.; Strizzi, L.; Hendrix, M. J. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res. 2010, 70, 10340-10350.
132. Strizzi, L.; Hardy, K. M.; Seftor, E. A.; Costa, F. F.; Kirschmann, D. A.; Seftor, R. E.; Postovit, L. M.; Hendrix, M. J. Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Res. 2009, 69, 7131-7134.
133. Postovit, L. M.; Seftor, E. A.; Seftor, R. E.; Hendrix, M. J. Targeting Nodal in malignant melanoma cells. Expert. Opin. Ther. Targets. 2007, 11, 497-505.
134. Huynh, C.; Poliseno, L.; Segura, M. F.; Medicherla, R.; Haimovic, A.; Menendez, S.; Shang, S.; Pavlick, A.; Shao, Y.; Darvishian, F.; Boylan, J. F.; Osman, I.; Hernando, E. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One 2011, 6, e25264.
135. Rawlings, J. S.; Rosler, K. M.; Harrison, D. A. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117, 1281-1283.
136. Niu, G.; Heller, R.; Catlett-Falcone, R.; Coppola, D.; Jaroszeski, M.; Dalton, W.; Jove, R.; Yu, H. Gene therapy with dominantnegative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999, 59, 5059-5063.
137. Messina, J. L.; Yu, H.; Riker, A. I.; Munster, P. N.; Jove, R. L.; Daud, A. I. Activated stat-3 in melanoma. Cancer Control. 2008, 15, 196-201.
138. Kreis, S.; Munz, G. A.; Haan, S.; Heinrich, P. C.; Behrmann, I. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol. Cancer Res. 2007, 5, 1331-1341.
139. Blaskovich, M. A.; Sun, J.; Cantor, A.; Turkson, J.; Jove, R.; Sebti, S. M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63, 1270-1279.
140. Krasil'nikov, M.; Shatskaya, V. Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. J. Steroid. Biochem. Mol. Biol. 2002, 82, 369-376.
141. Mirmohammadsadegh, A.; Marini, A.; Gustrau, A.; Delia, D.; Nambiar, S.; Hassan, M.; Hengge, U. R. Role of erythropoietin receptor expression in malignant melanoma. J. Invest. Dermatol. 2010, 130, 201-210.
142. Bill, M. A.; Bakan, C.; Benson, D. M., Jr.; Fuchs, J.; Young, G.; Lesinski, G. B. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol. Cancer Ther. 2009, 8, 2726-2735.
143. Bill, M. A.; Fuchs, J. R.; Li, C.; Yui, J.; Bakan, C.; Benson, D. M., Jr.; Schwartz, E. B.; Abdelhamid, D.; Lin, J.; Hoyt, D. G.; Fossey, S. L.; Young, G. S.; Carson, W. E., 3rd; Li, P. K.; Lesinski, G. B. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol. Cancer 2010, 9, 165.
144. Scutti, J. A.; Matsuo, A. L.; Pereira, F. V.; Massaoka, M. H.; Figueiredo, C. R.; Moreira, D. F.; Belizario, J. E.; Travassos, L. R. Role of SOCS-1 gene on melanoma cell growth and tumor development. Transl. Oncol. 2011, 4, 101-109.
145. Magrangeas, F.; Boisteau, O.; Denis, S.; Jacques, Y.; Minvielle, S. Negative regulation of onconstatin M signaling by suppressor of cytokine signaling (SOCS-3). Eur. Cytokine Netw. 2001, 12, 309-315.
146. Schultz, J.; Koczan, D.; Schmitz, U.; Ibrahim, S. M.; Pilch, D.; Landsberg, J.; Kunz, M. Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth. Clin. Exp. Metastasis 2010, 27, 133-140.
147. Mirmohammadsadegh, A.; Hassan, M.; Bardenheuer, W.; Marini, A.; Gustrau, A.; Nambiar, S.; Tannapfel, A.; Bojar, H.; Ruzicka, T.; Hengge, U. R. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J. Invest. Dermatol. 2006, 126, 2272-2280.
148. Hassel, J. C.; Winnemoller, D.; Schartl, M.; Wellbrock, C. STAT5 contributes to antiapoptosis in melanoma. Melanoma Res. 2008, 18, 378-385.
149. Maher, S. G.; Romero-Weaver, A. L.; Scarzello, A. J.; Gamero, A. M. Interferon: cellular executioner or white knight? Curr. Med. Chem. 2007, 14, 1279-1289.
150. Kovarik, J.; Boudny, V.; Kocak, I.; Lauerova, L.; Fait, V.; Vagundova, M. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int. J. Mol. Med. 2003, 12, 335-340.
151. Ascierto, P. A.; Kirkwood, J. M. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J. Transl. Med. 2008, 6, 62.
152. Fernandes, E.; Soans, E.; Xu, J.; Kieliszewski, M.; Evans, S. C. Novel fusion proteins of interferon alpha2b cause growth inhibition and induce JAK-STAT signaling in melanoma. J. Immunother. 2010, 33, 461-466.
153. Kortylewski, M.; Komyod, W.; Kauffmann, M. E.; Bosserhoff, A.; Heinrich, P. C.; Behrmann, I. Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J. Invest. Dermatol. 2004, 122, 414-422.
154. Kovarik, A.; Fojtova, M.; Boudny, V.; Adamkova, L.; Lauerova, L.; Kovarik, J. Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. Melanoma Res. 2005, 15, 481-488.
155. Fojtova, M.; Boudny, V.; Kovarik, A.; Lauerova, L.; Adamkova, L.; Souckova, K.; Jarkovsky, J.; Kovarik, J. Development of IFNgamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells. Br. J. Cancer 2007, 97, 231-237.
156. Guenterberg, K. D.; Grignol, V. P.; Raig, E. T.; Zimmerer, J. M.; Chan, A. N.; Blaskovits, F. M.; Young, G. S.; Nuovo, G. J.; Mundy, B. L.; Lesinski, G. B.; Carson, W. E., 3rd. Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol. Cancer Ther. 2010, 9, 510-520.
157. Levy, C.; Khaled, M.; Fisher, D. E. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 2006, 12, 406-414.
158. Cheli, Y.; Ohanna, M.; Ballotti, R.; Bertolotto, C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigm. Cell Melanoma Res. 2010, 23, 27-40.
159. Yajima, I.; Kumasaka, M. Y.; Thang, N. D.; Goto, Y.; Takeda, K.; Iida, M.; Ohgami, N.; Tamura, H.; Yamanoshita, O.; Kawamoto, Y.; Furukawa, K.; Kato, M. Molecular network associated with MITF in skin melanoma development and progression. J. Skin Cancer. 2011, 2011, 730170.
160. Garraway, L. A.; Widlund, H. R.; Rubin, M. A.; Getz, G.; Berger, A. J.; Ramaswamy, S.; Beroukhim, R.; Milner, D. A.; Granter, S. R.; Du, J.; Lee, C.; Wagner, S. N.; Li, C.; Golub, T. R.; Rimm, D. L.; Meyerson, M. L.; Fisher, D. E.; Sellers, W. R. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436, 117-122.
161. Vachtenheim, J.; Borovansk J. "Transcription physiology" of pigment formation in melanocytes: central role of MITF. Exp Dermatol. 2010, 19, 617-627.
162. Bertolotto, C.; Abbe, P.; Hemesath, T. J.; Bille, K.; Fisher, D. E.; Ortonne, J. P.; Ballotti, R. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J. Cell Biol. 1998, 142, 827-835.
163. Widlund, H. R.; Horstmann, M. A.; Price, E. R.; Cui, J.; Lessnick, S. L.; Wu, M.; He, X.; Fisher, D. E. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmiaassociated transcription factor. J. Cell Biol. 2002, 158, 1079-1087.
164. Mascarenhas, J. B.; Littlejohn, E. L.; Wolsky, R. J.; Young, K. P.; Nelson, M.; Salgia, R.; Lang, D. PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res. 2010, 23, 225-237.
165. Wellbrock, C.; Marais, R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 2005, 170, 703-708.
166. Mansky, K. C.; Sankar, U.; Han, J.; Ostrowski, M. C. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J. Biol. Chem. 2002, 277, 11077-11083.
167. Takeda, K.; Takemoto, C.; Kobayashi, I.; Watanabe, A.; Nobukuni, Y.; Fisher, D. E.; Tachibana, M. Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Hum. Mol. Genet. 2000, 9, 125-132.
168. Carreira, S.; Goodall, J.; Aksan, I.; La Rocca, S. A.; Galibert, M. D.; Denat, L.; Larue, L.; Goding, C. R. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005, 433, 764-769.
169. Loercher, A. E.; Tank, E. M.; Delston, R. B.; Harbour, J. W. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 2005, 168, 35-40.
170. Carreira, S.; Liu, B.; Goding, C. R. The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J. Biol. Chem. 2000, 275, 21920-21927.
171. Busca, R.; Berra, E.; Gaggioli, C.; Khaled, M.; Bille, K.; Marchetti, B.; Thyss, R.; Fitsialos, G.; Larribere, L.; Bertolotto, C.; Virolle, T.; Barbry, P.; Pouyssegur, J.; Ponzio, G.; Ballotti, R. Hypoxiainducible factor 1{alpha} is a new target of microphthalmiaassociated transcription factor (MITF) in melanoma cells. J. Cell Biol. 2005, 170, 49-59.
172. McGill, G. G.; Haq, R.; Nishimura, E. K.; Fisher, D. E. c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem. 2006, 281, 10365-10373.
173. Carreira, S.; Goodall, J.; Denat, L.; Rodriguez, M.; Nuciforo, P.; Hoek, K. S.; Testori, A.; Larue, L.; Goding, C. R. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006, 20, 3426-3439.
174. Mani, S. A.; Guo, W.; Liao, M. J.; Eaton, E. N.; Ayyanan, A.; Zhou, A. Y.; Brooks, M.; Reinhard, F.; Zhang, C. C.; Shipitsin, M.; Campbell, L. L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R. A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
175. Yasumoto, K.; Yokoyama, K.; Takahashi, K.; Tomita, Y.; Shibahara, S. Functional analysis of microphthalmia-associated transcription factor in pigment cell-specific transcription of the human tyrosinase family genes. J. Biol. Chem. 1997, 272, 503-509.
176. Hoek, K. S.; Goding, C. R. Cancer stem cells versus phenotypeswitching in melanoma. Pigment Cell Melanoma Res. 2010, 23, 746-759.
177. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature. 2007, 445, 851-857.
178. Salti, G. I.; Manougian, T.; Farolan, M.; Shilkaitis, A.; Majumdar, D.; Das Gupta, T. K. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 2000, 60, 5012-6.
179. Carlson, J. A.; Linette, G. P.; Aplin, A.; Ng, B.; Slominski, A. Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol. Clin. 2007, 25, 541-557.
180. Brenner, M.; Degitz, K.; Besch, R.; Berking, C. Differential expression of melanoma-associated growth factors in keratinocytes and fibroblasts by ultraviolet A and ultraviolet B radiation. Br. J. Dermatol. 2005, 153, 733-739.
181. Rivera, R. S.; Nagatsuka, H.; Gunduz, M.; Cengiz, B.; Gunduz, E.; Siar, C. H.; Tsujigiwa, H.; Tamamura, R.; Han, K. N.; Nagai, N. Ckit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 2008, 452, 27-32.
182. Papaspyrou, G.; Garbe, C.; Schadendorf, D.; Werner, J. A.; Hauschild, A.; Egberts, F. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Melanoma Res. 2011, 21, 475-482.
183. Antonescu, C. R.; Busam, K. J.; Francone, T. D.; Wong, G. C.; Guo, T.; Agaram, N. P.; Besmer, P.; Jungbluth, A.; Gimbel, M.; Chen, C. T.; Veach, D.; Clarkson, B. D.; Paty, P. B.; Weiser, M. R. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int. J. Cancer 2007, 121, 257-264.
184. Ashida, A.; Takata, M.; Murata, H.; Kido, K.; Saida, T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int. J. Cancer 2009, 124, 862-868.
185. Mol, C. D.; Dougan, D. R.; Schneider, T. R.; Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B. C.; Wilson, K. P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 2004, 279, 31655-31663.
186. Mimeault, M.; Batra, S. K. Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J. Clin. Oncol. 2012, 3, 32-42.
187. Natarajan, N.; Telang, S.; Miller, D.; Chesney, J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 2011, 71, 1233-1250.
188. Montero, J. C.; Seoane, S.; Ocana, A.; Pandiella, A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res. 2011, 17, 5546-5552.
189. Halaban, R.; Rubin, J. S.; Funasaka, Y.; Cobb, M.; Boulton, T.; Faletto, D.; Rosen, E.; Chan, A.; Yoko, K.; White, W.; et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene. 1992, 7, 2195-2206.
190. Beuret, L.; Flori, E.; Denoyelle, C.; Bille, K.; Busca, R.; Picardo, M.; Bertolotto, C.; Ballotti, R. Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J. Biol. Chem. 2007, 282, 14140-14147.
191. Braeuer, R. R.; Zigler, M.; Villares, G. J.; Dobroff, A. S.; Bar-Eli, M. Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin. Cancer Biol. 2011, 21, 83-88.
192. Kelly, R. J.; Rixe, O. Axitinib (AG-013736). Recent Results Cancer Res. 2010, 184, 33-44.
193. Boyle, G. M.; Pedley, J.; Martyn, A. C.; Banducci, K. J.; Strutton, G. M.; Brown, D. A.; Breit, S. N.; Parsons, P. G. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J. Invest. Dermatol. 2009, 129, 383-391.
194. Schmidt, P.; Abken, H. The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2011, 2, 313-320.
195. Kong, Y.; Kumar, S. M.; Xu, X. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med. 2010, 134, 1740-1749.
196. Schatton, T.; Frank, M. H. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 2008, 21, 39-55.
197. Zabierowski, S. E.; Fukunaga-Kalabis, M.; Li, L.; Herlyn, M. Dermis-derived stem cells: a source of epidermal melanocytes and melanoma? Pigment Cell and Melanoma Research 2011, 24, 422-429.
198. Hoerter, J. D.; Bradley, P.; Casillas, A.; Chambers, D.; Denholm, C.; Johnson, K.; Weiswasser, B. Extrafollicular dermal melanocyte stem cells and melanoma. Stem Cells International. 2012, 407079, 10 p.
199. Monzani, E.; Facchetti, F.; Galmozzi, E.; Corsini, E.; Benetti, A.; Cavazzin, C.; Gritti, A.; Piccinini, A.; Porro, D.; Santinami, M.; Invernici, G.; Parati, E.; Alessandri, G.; La Porta, C. A. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007, 43, 935-946.
200. Na, Y. R.; Seok, S. H.; Kim, D. J.; Han, J. H.; Kim, T. H.; Jung, H.; Lee, B. H.; Park, J. H. Isolation and characterization of spheroid cells from human malignant melanoma cell line WM-266-4. Tumor Biology 2009, 30, 300-309.
201. Quintana, E.;, Shackleton, M.; Sabel, M. S.; Fullen, D. R.; Johnson, T. M.; Morrison, S. J. Efficient tumour formation by single human melanoma cells. Nature. 2008, 456, 593-598.
202. Hendrix, M. J.; Seftor, E. A.; Hess, A. R.; Seftor, R. E. Molecular plasticity of human melanoma cells. Oncogene 2003, 22, 3070-3075.
203. Bittner, M.; Meltzer, P.; Chen, Y.; Jiang, Y.; Seftor, E.; Hendrix, M.; Radmacher, M.; Simon, R.; Yakhini, Z.; Ben-Dor, A.; Sampas, N.; Dougherty, E.; Wang, E.; Marincola, F.; Gooden, C.; Lueders, J.; Glatfelter, A.; Pollock, P.; Carpten, J.; Gillanders, E.; Leja, D.; Dietrich, K.; Beaudry, C.; Berens, M.; Alberts, D.; Sondak, V. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406, 536-540.
204. Weeraratna, A. T.; Jiang, Y.; Hostetter, G.; Rosenblatt, K.; Duray, P.; Bittner, M. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1, 279-288.
205. Klein, W. M.; Wu, B. P.; Zhao, S.; Wu, H.; Klein-Szanto, A. J.; Tahan, S. R. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 2007, 20. 102-107.
206. Simpson, A. J.; Caballero, O. L.; Jungbluth, A.; Chen, Y. T., Old, L. J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5, 615-625.
207. Schatton, T.; Murphy, G. F.; Frank, N. Y.; Yamaura, K.; Waaga-Gasser, A. M.; Gasser, M.; Zhan, Q.; Jordan, S.; Duncan, L. M.; Weishaupt, C.; Fuhlbrigge, R. C.; Kupper, T. S.; Sayegh, M. H.; Frank, M. H. Identification of cells initiating human melanomas. Nature 2008, 451, 345-349.
208. Frank, N. Y.; Margaryan, A.; Huang, Y.; Schatton, T.; Waaga-Gasser, A. M.; Gasser, M.; Sayegh, M. H.; Sadee, W.; Frank, M. H. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005, 65, 4320-4333.
209. Linley, A. J.; Mathieu, M. G.; Miles, A. K.; Rees, R. C.; McArdle, S. E.; Regad T. The helicase HAGE expressed by malignant melanomainitiating cells is required for tumor cell proliferation in vivo. J. Biol. Chem. 2012; 287, 13633-13643.